PDL BIOPHARMA, INC.

Form 3 April 18, 2019

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Evofem Biosciences, Inc. [EVFM] PDL BIOPHARMA, INC. (Month/Day/Year) 04/11/2019 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) 932 SOUTHWOOD (Check all applicable) **BOULEVARD** (Street) 6. Individual or Joint/Group _X__ 10% Owner Director Officer Other Filing(Check Applicable Line) (give title below) (specify below) _X_ Form filed by One Reporting Person **INCLINE** Form filed by More than One VILLAGE. NVÂ 89451 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 5) (Instr. 4) Form: Direct (D) or Indirect (I) (Instr. 5) Â Common Stock 6,666,667 D Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title	Security	Security: Direct (D)	

Edgar Filing: PDL BIOPHARMA, INC. - Form 3

Date Expiration Amount or or Indirect

Exercisable Date Number of (I)

Shares (Instr. 5)

Warrants $10/11/2019 \ 04/11/2026 \ \frac{\text{Common}}{\text{Stock}} \ \frac{1,666,667}{(1)} \ \$ 6.38 \ D \ \hat{A}$

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

PDL BIOPHARMA, INC.

932 SOUTHWOOD BOULEVARD Â Â X Â

INCLINE VILLAGE, NVÂ 89451

Signatures

PDL BioPharma, Inc., By: /s/ Peter S. Garcia, Name: Peter S. Garcia, Title: Chief Financial Officer

04/18/2019

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Pursuant to that certain Securities Purchase Agreement, dated as of April 10, 2019, by and among the Issuer, the Reporting Person and the other parties thereto, prior to approval by the Issuer's shareholders of the issuance of the shares of Common Stock and Warrants, the Reporting Person is prohibited from exercising any portion of the Warrants to the extent the Reporting Person would beneficially own more than 19.99% of the Issuer's outstanding Common Stock immediately after exercise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2